1
|
Abstract
Heart failure is a clinical syndrome that may result from different disease states or conditions that injure the myocardium. The activation of circulating neurohormones, particularly aldosterone, may play a pivotal role in left ventricular (LV) remodelling. The Randomized Aldactone Evaluation Study and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival trial have emphasised the clinical importance of aldosterone. This review addresses some of the proposed mechanisms of LV remodelling in heart failure.
Collapse
Affiliation(s)
- Frederick K Shieh
- Boston University Medical School, Boston University Medical Center, Boston, Massechussetts, USA
| | | | | |
Collapse
|
2
|
Fayssoil A, Drouet T, Luis D, Orlikowski D, Alamowitch S, Annane D. Acute ischemic stroke in gamma-sarcoglycanopathy. Presse Med 2012; 42:484-6. [PMID: 23040950 DOI: 10.1016/j.lpm.2012.07.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2012] [Accepted: 07/17/2012] [Indexed: 11/30/2022] Open
|
3
|
Seguchi O, Takashima S, Yamazaki S, Asakura M, Asano Y, Shintani Y, Wakeno M, Minamino T, Kondo H, Furukawa H, Nakamaru K, Naito A, Takahashi T, Ohtsuka T, Kawakami K, Isomura T, Kitamura S, Tomoike H, Mochizuki N, Kitakaze M. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest 2007; 117:2812-24. [PMID: 17885681 PMCID: PMC1978424 DOI: 10.1172/jci30804] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2006] [Accepted: 06/26/2007] [Indexed: 02/04/2023] Open
Abstract
Marked sarcomere disorganization is a well-documented characteristic of cardiomyocytes in the failing human myocardium. Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC2v), which is involved in the development of human cardiomyopathy, is an important structural protein that affects physiologic cardiac sarcomere formation and heart development. Integrated cDNA expression analysis of failing human myocardia uncovered a novel protein kinase, cardiac-specific myosin light chain kinase (cardiac-MLCK), which acts on MLC2v. Expression levels of cardiac-MLCK were well correlated with the pulmonary arterial pressure of patients with heart failure. In cultured cardiomyocytes, knockdown of cardiac-MLCK by specific siRNAs decreased MLC2v phosphorylation and impaired epinephrine-induced activation of sarcomere reassembly. To further clarify the physiologic roles of cardiac-MLCK in vivo, we cloned the zebrafish ortholog z-cardiac-MLCK. Knockdown of z-cardiac-MLCK expression using morpholino antisense oligonucleotides resulted in dilated cardiac ventricles and immature sarcomere structures. These results suggest a significant role for cardiac-MLCK in cardiogenesis.
Collapse
Affiliation(s)
- Osamu Seguchi
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Seiji Takashima
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Satoru Yamazaki
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Masanori Asakura
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Yoshihiro Asano
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Yasunori Shintani
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Masakatsu Wakeno
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Tetsuo Minamino
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Hiroya Kondo
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Hidehiko Furukawa
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Kenji Nakamaru
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Asuka Naito
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Tomoko Takahashi
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Toshiaki Ohtsuka
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Koichi Kawakami
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Tadashi Isomura
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Soichiro Kitamura
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Hitonobu Tomoike
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Naoki Mochizuki
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| | - Masafumi Kitakaze
- Department of Cardiovascular Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Department of Cardiovascular Medicine and
Health Care Center, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Core Technology Research Laboratories, Sankyo Co. Ltd., Shinagawa, Tokyo, Japan.
Division of Molecular and Developmental Biology, National Institute of Genetics, Mishima, Shizuoka, Japan.
Hayama Heart Center, Hayama, Kanagawa, Japan
| |
Collapse
|
4
|
Abstract
Cardiac troponin I (TnI) knockout mice exhibit a phenotype of sudden death at 17–18 days after birth due to a progressive loss of TnI. The objective of this study was to gain insight into the physiological consequences of TnI depletion and the cause of death in these mice. Cardiac function was monitored serially between 12 and 17 days of age by using high-resolution ultrasonic imaging and Doppler echocardiography. Two-dimensional B-mode and anatomical M-mode imaging and Doppler echocardiography were performed using a high-frequency (∼20–45 MHz) ultrasound imaging system on homozygous cardiac TnI mutant mice (cTnI−/−) and wild-type littermates. On day 12, cTnI−/−mice were indistinguishable from wild-type mice in terms of heart rate, atrial and LV (LV) chamber dimensions, LV posterior wall thickness, and body weight. By days 16 through 17, wild-type mice showed up to a 40% increase in chamber dimensions due to normal growth, whereas cTnI−/−mice showed increases in atrial dimensions of up to 97% but decreases in ventricular dimensions of up to 70%. Mitral Doppler analysis revealed prolonged isovolumic relaxation time and pronounced inversion of the mitral E/A ratio (early ventricular filling wave-to-late atrial contraction filling wave) only in cTnI−/−mice indicative of impaired LV relaxation. cTnI−/−mouse hearts showed clear signs of failure on day 17, characterized by >50% declines in cardiac output, ejection fraction, and fractional shortening. B-mode echocardiography showed a profoundly narrowed tube-like LV and enlarged atria at this time. Our data are consistent with TnI deficiency causing impaired LV relaxation, which leads to diastolic heart failure in this model.
Collapse
MESH Headings
- Animals
- Cardiac Output
- Cardiac Output, Low/diagnostic imaging
- Cardiac Output, Low/etiology
- Cardiac Output, Low/genetics
- Cardiac Output, Low/physiopathology
- Disease Progression
- Echocardiography, Doppler
- Electrocardiography
- Genotype
- Heart Atria/diagnostic imaging
- Heart Atria/embryology
- Heart Atria/physiopathology
- Heart Ventricles/diagnostic imaging
- Heart Ventricles/metabolism
- Heart Ventricles/physiopathology
- Mice
- Mice, Transgenic
- Myocardial Contraction/genetics
- Phenotype
- Time Factors
- Troponin I/deficiency
- Troponin I/genetics
- Troponin I/metabolism
- Ventricular Dysfunction, Left/complications
- Ventricular Dysfunction, Left/diagnostic imaging
- Ventricular Dysfunction, Left/genetics
- Ventricular Dysfunction, Left/metabolism
- Ventricular Dysfunction, Left/physiopathology
Collapse
Affiliation(s)
- Jing Liu
- Department of Biomedical Science and Center for Molecular Biology and Biotechnology, Florida Atlantic University, 777 Glades Rd., Boca Raton, FL 33431, USA
| | | | | | | | | |
Collapse
|
5
|
Watanabe E, Yasui K, Kamiya K, Yamaguchi T, Sakuma I, Honjo H, Ozaki Y, Morimoto S, Hishida H, Kodama I. Upregulation of KCNE1 induces QT interval prolongation in patients with chronic heart failure. Circ J 2007; 71:471-8. [PMID: 17384445 DOI: 10.1253/circj.71.471] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Prolongation of the action potential duration (APD) is observed in ventricular myocytes isolated from the failing heart. The rapid component (I(Kr)) and the slow component (I(Ks)) of the delayed-rectifier potassium current (I(K)) are major determinants of the APD, but less information is available on the genomic modulation of I(K) in the remodeled human heart. The aim of the current study was to examine the relationship between I(K) transcripts and QT interval in surface electrocardiogram in patients with chronic heart failure (CHF). METHODS AND RESULTS Total RNA was extracted from right ventricle endomyocardial biopsy samples in 21 CHF patients (age: 53+/-4 years, mean +/- SEM). The KCNH2 and KCNQ1 levels did not differ significantly between controls (New York Heart Association (NYHA) I, n=10) and CHF patients (NYHA II or III, n=11), whereas the KCNE1 level was significantly higher in CHF patients than in controls (relative mRNA levels normalized to GAPDH expression: 6.16+/-0.31 vs 7.70+/-0.46, p<0.05). The KCNE1/KCNQ1 ratio was higher in CHF patients than in controls (0.92+/-0.02 vs 1.06+/-0.05, p<0.05) and the KCNE1-KCNQ1 ratio was positively correlated with QT interval (r=0.70, p<0.05). Increasing the KCNE1 concentration caused a shift in activation voltage and slowed the activation kinetics of the KCNE1-KCNQ1 currents expressed in Xenopus oocytes. Prolongation of the APD and decrease in I(Ks) with increasing the amount of KCNE1 concentration were well predicted in a computer simulation. CONCLUSIONS In mild-to-moderate CHF patients, the relative abundance of KCNE1 compared to KCNQ1 genes, at least in part, might contribute to the preferential prolongation of QT interval through reducing the net outward current during the plateau of the action potential.
Collapse
Affiliation(s)
- Eiichi Watanabe
- Division of Cardiology, Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
Heart failure is a major cause of morbidity and mortality in contemporary societies. Although progress in conventional treatment modalities is making steady and incremental gains to reduce this disease burden, there remains a need to explore new and potentially therapeutic approaches. Gene therapy, for example, was initially envisioned as a treatment strategy for inherited monogenic disorders. It is now apparent that gene therapy has broader potential that also includes acquired polygenic diseases, such as heart failure. Advances in the understanding of the molecular basis of conditions such as these, together with the evolution of increasingly efficient gene transfer technology, has placed congestive heart failure within reach of gene-based therapy.
Collapse
Affiliation(s)
- Hung Ly
- Cardiology Division, Cardiovascular Research Center, the Cardiology Laboratory of Integrative Physiology, Imaging at Massachusetts General Hospital, Boston, MA, USA
| | | | | | | |
Collapse
|
7
|
Finsterer J, Stollberger C. Genetic background of left ventricular hypertrabeculation/non-compaction with stroke. Europace 2007; 9:333. [PMID: 17363428 DOI: 10.1093/europace/eum012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Canham RM, Das SR, Leonard D, Abdullah SM, Mehta SK, Chung AK, Li JL, Victor RG, Auchus RJ, Drazner MH. Alpha2cDel322-325 and beta1Arg389 adrenergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular volume. J Am Coll Cardiol 2006; 49:274-6. [PMID: 17222742 DOI: 10.1016/j.jacc.2006.10.016] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
MESH Headings
- Adult
- Black or African American/genetics
- Alleles
- Cardiac Output, Low/ethnology
- Cardiac Output, Low/genetics
- Cohort Studies
- Female
- Genotype
- Heart Failure/diagnosis
- Heart Failure/ethnology
- Heart Failure/genetics
- Humans
- Hypertrophy, Left Ventricular/ethnology
- Hypertrophy, Left Ventricular/genetics
- Male
- Middle Aged
- Polymorphism, Genetic
- Receptors, Adrenergic, alpha-2/genetics
- Receptors, Adrenergic, beta-1/genetics
- Sensitivity and Specificity
- Stroke Volume/genetics
- Ventricular Dysfunction, Left/ethnology
- Ventricular Dysfunction, Left/genetics
- White People/genetics
Collapse
|
9
|
Gubaev KI, Nasibullin TR, Zakirova AN, Mustafina OE. [Association of polymorphic markers I/D of gene ACE and A1166C of gene AT2R1 with ischemic chronic heart failure in the Russian and Tatar populations of Bashkortostan Republic]. Genetika 2006; 42:1712-7. [PMID: 17326392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Polymerase chain reaction was used to study the association of polymorphic markers I/D of the angiotensin-converting enzyme gene (ACE) and A1166C of the angiotensin II type 1 receptor gene (AT2R1) with chronic heart failure (CHF) in Russian and Tatar patients that had had myocardial infarction. In Russian patients aged 50 years or younger that had had macrofocal myocardial infarction, the CC genotype of the A1166C polymorphic marker of gene AT2R1 was associated with an increased risk of CHF (OR = 11.36). Genotype DD and allele D of the I/D polymorphic marker of gene ACE were associated with a more severe CHF (functional class III-IV) in Russian patients (OR = 3.50 and 2.06). In Tatar patients, polymorphic markers I/D of gene ACE and A1166C of gene AT2R1 were not associated with CHF.
Collapse
|
10
|
Felkin LE, Birks EJ, George R, Wong S, Khaghani A, Yacoub MH, Barton PJR. A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support. J Heart Lung Transplant 2006; 25:1413-9. [PMID: 17178334 DOI: 10.1016/j.healun.2006.09.006] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2006] [Revised: 07/26/2006] [Accepted: 09/09/2006] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Mechanisms underlying the rapid deterioration of heart failure patients who subsequently require left ventricular assist device (LVAD) support are poorly understood. Matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) play a key role in myocardial remodelling and heart failure. We hypothesized that MMP and TIMP expression would be altered in these patients. METHODS Quantitative polymerase chain reaction was used to measure myocardial messenger RNA levels of MMP1 to MMP14, TIMP1 to TIMP4, collagen I and collagen III in 24 dilated cardiomyopathy (DCM) patients with deteriorating clinical status who required LVAD support (LVAD Group) and in 7 stable DCM patients undergoing transplantation without need for LVAD support (Tx Group). RESULTS Levels of MMP1, MMP8 and TIMP4 were higher in the LVAD Group compared with the Tx Group (188% +/- 141%, 646% +/- 432%, and 66% +/- 33% higher, respectively, p < 0.05) whereas MMP2, MMP9, MMP10, MMP11, and MMP14 levels were similar. MMP3, MMP7, MMP12, and MMP13 were undetectable. All TIMPs were generally higher in the LVAD group, but only TIMP4 reached significance. Collagen I and III were not altered. We tested for correlations between MMP and TIMP expression with myocardial cytokine levels. MMP8 correlated positively with interleukin-6 and interleukin-1beta, suggesting a link between cytokines and MMPs in these patients. CONCLUSIONS The data show that high myocardial collagenase (MMP1 and MMP8) expression without compensatory changes in collagen or TIMP expression is a feature of patients requiring LVAD support. This may be linked in part to elevated cytokine expression and suggests collagenase activity may be an important therapeutic target in deteriorating heart failure.
Collapse
Affiliation(s)
- Leanne E Felkin
- National Heart and Lung Institute, Imperial College London, Heart Science Centre, Harefield, Middlesex
| | | | | | | | | | | | | |
Collapse
|
11
|
Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2006; 25:297-308. [PMID: 17126554 PMCID: PMC1850107 DOI: 10.1016/j.nbd.2006.09.016] [Citation(s) in RCA: 113] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2006] [Revised: 09/14/2006] [Accepted: 09/21/2006] [Indexed: 11/19/2022] Open
Abstract
Recent evidence suggests that mutant huntingtin protein-induced energetic perturbations contribute to neuronal dysfunction in Huntington's disease (HD). Given the ubiquitous expression of huntingtin, other cell types with high energetic burden may be at risk for HD-related dysfunction. Early-onset cardiovascular disease is the second leading cause of death in HD patients; a direct role for mutant huntingtin in this phenomenon remains unevaluated. Here we tested the hypothesis that expression of mutant huntingtin is sufficient to induce cardiac dysfunction, using a well-described transgenic model of HD (line R6/2). R6/2 mice developed cardiac dysfunction by 8 weeks of age, progressing to severe failure at 12 weeks, assessed by echocardiography. Limited evidence of cardiac remodeling (e.g. hypertrophy, fibrosis, apoptosis, beta(1) adrenergic receptor downregulation) was observed. Immunogold electron microscopy demonstrated significant elevations in nuclear and mitochondrial polyglutamine presence in the R6/2 myocyte. Significant alterations in mitochondrial ultrastructure were seen, consistent with metabolic stress. Increased cardiac lysine acetylation and protein nitration were observed and were each significantly associated with impairments in cardiac performance. These data demonstrate that mutant huntingtin expression has potent cardiotoxic effects; cardiac failure may be a significant complication of this important experimental model of HD. Investigation of the potential cardiotropic effects of mutant huntingtin in humans may be warranted.
Collapse
Affiliation(s)
- Michael J. Mihm
- Center for Cardiovascular Medicine, Columbus Children’s Research Institute, 700 Children’s Drive, Columbus, Ohio 43205
- Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210
| | - Deborah M. Amann
- Center for Cardiovascular Medicine, Columbus Children’s Research Institute, 700 Children’s Drive, Columbus, Ohio 43205
| | - Brandon L. Schanbacher
- Center for Cardiovascular Medicine, Columbus Children’s Research Institute, 700 Children’s Drive, Columbus, Ohio 43205
| | - Ruth A. Altschuld
- The Ohio State University Biophysics Program and Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio 43210
| | - John Anthony Bauer
- Center for Cardiovascular Medicine, Columbus Children’s Research Institute, 700 Children’s Drive, Columbus, Ohio 43205
- Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210
- Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio 43210
- * Corresponding Authors: Division of Pharmacology, College of Pharmacy, The Ohio State University, 412 Riffe Building, 496 West 12 Avenue, Columbus, OH 43221, Phone: (614) 292-6636, e-mail: (J.A.B) and (K.R.H)
| | - Kari R. Hoyt
- Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210
- * Corresponding Authors: Division of Pharmacology, College of Pharmacy, The Ohio State University, 412 Riffe Building, 496 West 12 Avenue, Columbus, OH 43221, Phone: (614) 292-6636, e-mail: (J.A.B) and (K.R.H)
| |
Collapse
|
12
|
A legacy of heart failure. Duke Med Health News 2006; 12:11. [PMID: 17225311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
|
13
|
Abstract
OBJECTIVE Chronic heart failure (CHF) is associated with neurohumoral activation and decrements in pulmonary function (PF). The beta2-adrenergic receptor (ADRB2) modulates airway smooth muscle tone and influences lung fluid clearance. Common polymorphisms of the ADRB2 are associated with differences in ADRB2 function and therefore could differentially influence PF in patients with CHF. METHODS We studied baseline PF according to genetic variations of the ADRB2 at amino acid 16 (ie, arginine [Arg] or glycine [Gly]) in 126 CHF patients (mean [+/- SEM] age, 56 +/- 1 years; left ventricular ejection fraction [LVEF], 29 +/- 1%; body mass index [BMI], 28 +/- 0.4 kg/m2) and in 100 healthy control subjects (mean age, 50 +/- 2 years; LVEF, 63 +/- 0.7%; BMI, 25 +/- 0.3 kg/m2). RESULTS Venous epinephrine levels did not differ between CHF patients and control subjects or across genotype groups; however, norepinephrine levels were higher in CHF patients and was greater in ArgArg patients compared to GlyGly patients (p < 0.05). PF did not differ according to genotype in control subjects; however, CHF patients who were homozygous for Arg had reduced PF relative to heterozygotes or those subjects who were homozygous for Gly (vital capacity: ArgArg group, 82 +/- 3% predicted; ArgGly group, 92 +/- 2% predicted; GlyGly group, 93 +/- 2% predicted; FVC: ArgArg group, 77 +/- 3% predicted; ArgGly group, 89 +/- 2% predicted; GlyGly group, 90 +/- 2% predicted; FEV1: ArgArg group, 75 +/- 4% predicted; ArgGly group, 86 +/- 3% predicted; GlyGly group, 87 +/- 2% predicted; diffusing capacity of the lung for carbon monoxide: ArgArg group, 76 +/- 4% predicted; ArgGly group, 83 +/- 2% predicted; GlyGly group, 85 +/- 2% predicted; p < 0.05). In addition, there was a modest correlation between mitral valve inflow deceleration time and PF in CHF patients (r = 0.42; p < 0.01), but not in control subjects. CONCLUSIONS These data suggest that genetic variation of the ADRB2 is associated with differences in PF in CHF patients but not in healthy subjects, which may be related to an increased susceptibility of the homozygous Arg subjects to agonist-mediated desensitization of ADRB2s in the lungs, or related to an influence of this polymorphism on cardiac diastolic properties.
Collapse
Affiliation(s)
- Eric M Snyder
- Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
| | | | | |
Collapse
|
14
|
Abstract
In this era of genomics, new technologies and the information that they generate have a wide range of potential applications to heart failure. Though there has not been widespread practical use of genomic information in everyday practice, there are many examples of how this information is beginning to transform the way we look at disease states in terms of diagnosis, prognosis, and treatment. The experience of oncology and other fields helps inform the heart failure field of not only the use of this information in investigating diagnosis, prognosis, and treatment response, but the reciprocal nature of this information. This information can be clinically useful (for instance, predicting treatment response) as well as further drive laboratory investigation (teasing out the biological pathways in non-responders to treatment can be a focus of new drug discovery); this is the essence of translational medicine. We believe that this is a good time to review where new technologies and information they generate can be placed into our classic understanding of heart failure: that is how we might redefine cardiomyopathy given our new information. Here we will review genomic evidence to date and how it can and may be considered in the evaluation and management of cardiomyopathies.
Collapse
Affiliation(s)
- Mark P Donahue
- Duke University Medical Center Department of Medicine, Division of Cardiovascular Medicine, Durham, North Carolina 27710, USA.
| | | | | |
Collapse
|
15
|
Biolo A, Rosa AS, Mazzotti NG, Martins S, Belló-Klein A, Rohde LE, Clausell N. The role of adrenergic receptor polymorphisms in heart failure. Braz J Med Biol Res 2006; 39:1281-90. [PMID: 17053838 DOI: 10.1590/s0100-879x2006001000003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2005] [Accepted: 07/11/2006] [Indexed: 11/22/2022] Open
Abstract
The main function of the cardiac adrenergic system is to regulate cardiac work both in physiologic and pathologic states. A better understanding of this system has permitted the elucidation of its role in the development and progression of heart failure. Regardless of the initial insult, depressed cardiac output results in sympathetic activation. Adrenergic receptors provide a limiting step to this activation and their sustained recruitment in chronic heart failure has proven to be deleterious to the failing heart. This concept has been confirmed by examining the effect of beta-blockers on the progression of heart failure. Studies of adrenergic receptor polymorphisms have recently focused on their impact on the adrenergic system regarding its adaptive mechanisms, susceptibilities and pharmacological responses. In this article, we review the function of the adrenergic system and its maladaptive responses in heart failure. Next, we discuss major adrenergic receptor polymorphisms and their consequences for heart failure risk, progression and prognosis. Finally, we discuss possible therapeutic implications resulting from the understanding of polymorphisms and the identification of individual genetic characteristics.
Collapse
MESH Headings
- Cardiac Output, Low/genetics
- Cardiac Output, Low/physiopathology
- Disease Progression
- Humans
- Polymorphism, Genetic/genetics
- Prognosis
- Receptors, Adrenergic, alpha/genetics
- Receptors, Adrenergic, alpha/physiology
- Receptors, Adrenergic, beta/genetics
- Receptors, Adrenergic, beta/physiology
Collapse
Affiliation(s)
- A Biolo
- Grupo de Insuficiência Cardíaca e Transplante, Serviço de Cardiologia, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, 90035-003 Porto Alegre, RS, Brazil
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Chronic heart failure (CHF) is a leading cause of mortality in developed countries. Angiotensin II (Ang II) plays an important role in the development and progression of CHF. Many of the important functions of Ang II are mediated by the Ang II type 1 receptor (AT(1)R), including the increase in sympathetic nerve activity in CHF. However, the central regulation of the AT(1)R in the setting of CHF is not well understood. This study investigated the AT(1)R in the rostral ventrolateral medulla (RVLM) of rabbits with CHF, its downstream pathway, and its gene regulation by the transcription factor activator protein 1 (AP-1). Studies were performed in 5 groups of rabbits: sham (n=5), pacing-induced (3 to 4 weeks) CHF (n=5), CHF with intracerebroventricular (ICV) losartan treatment (n=5), normal with ICV Ang II treatment (n=5), and normal with ICV Ang II plus losartan treatment (n=5). AT(1)R mRNA and protein expressions, plasma Ang II, and AP-1-DNA binding activity were significantly higher in RVLM of CHF compared with Sham rabbits (240.4+/-30.2%, P<0.01; 206.6+/-25.8%, P<0.01; 280+/-36.5%, P<0.05; 207+/-16.4%, P<0.01, respectively). Analysis of the stress-activated protein kinase/Jun N-terminal kinase (SAPK/JNK) pathway showed that phosphorylated c-Jun proteins, phosphorylated JNK proteins, and JNK activity increased significantly in RVLM of CHF compared with sham (262.9+/-48.1%, 213.8+/-27.7%, 148.2+/-10.1% of control, respectively). Importantly, ICV losartan in CHF rabbits attenuated these increases. ICV Ang II in normal rabbits simulated the molecular changes seen in CHF. This effect was blocked by concomitant ICV losartan. In addition, Ang II-induced AT(1)R expression was blocked by losartan and a JNK inhibitor, but not by extracellular signal-regulated kinase or p38 MAP kinase inhibitors in a neuronal cell culture. These data suggest that central Ang II activates the AT(1)R, SAPK/JNK pathway. AP-1 may further regulate gene expression in RVLM in the CHF state.
Collapse
Affiliation(s)
- Dongmei Liu
- Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, 985850 Nebraska Medical Center, Omaha, NE 68198-5850, USA
| | | | | | | | | |
Collapse
|
17
|
Hannenhalli S, Putt ME, Gilmore JM, Wang J, Parmacek MS, Epstein JA, Morrisey EE, Margulies KB, Cappola TP. Transcriptional genomics associates FOX transcription factors with human heart failure. Circulation 2006; 114:1269-76. [PMID: 16952980 DOI: 10.1161/circulationaha.106.632430] [Citation(s) in RCA: 167] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Specific transcription factors (TFs) modulate cardiac gene expression in murine models of heart failure, but their relevance in human subjects remains untested. We developed and applied a computational approach called transcriptional genomics to test the hypothesis that a discrete set of cardiac TFs is associated with human heart failure. METHODS AND RESULTS RNA isolates from failing (n=196) and nonfailing (n=16) human hearts were hybridized with Affymetrix HU133A arrays, and differentially expressed heart failure genes were determined. TF binding sites overrepresented in the -5-kb promoter sequences of these heart failure genes were then determined with the use of public genome sequence databases. Binding sites for TFs identified in murine heart failure models (MEF2, NKX, NF-AT, and GATA) were significantly overrepresented in promoters of human heart failure genes (P<0.002; false discovery rate 2% to 4%). In addition, binding sites for FOX TFs showed substantial overrepresentation in both advanced human and early murine heart failure (P<0.002 and false discovery rate <4% for each). A role for FOX TFs was supported further by expression of FOXC1, C2, P1, P4, and O1A in failing human cardiac myocytes at levels similar to established hypertrophic TFs and by abundant FOXP1 protein in failing human cardiac myocyte nuclei. CONCLUSIONS Our results provide the first evidence that specific TFs identified in murine models (MEF2, NKX, NFAT, and GATA) are associated with human heart failure. Moreover, these data implicate specific members of the FOX family of TFs (FOXC1, C2, P1, P4, and O1A) not previously suggested in heart failure pathogenesis. These findings provide a crucial link between animal models and human disease and suggest a specific role for FOX signaling in modulating the hypertrophic response of the heart to stress in humans.
Collapse
Affiliation(s)
- Sridhar Hannenhalli
- Department of Genetics and Penn Center for Bioinformatics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Taylor AL, Cohn JN, Feldman AM, Worcel M. Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure. J Am Coll Cardiol 2006; 48:1277-82. [PMID: 16979018 DOI: 10.1016/j.jacc.2006.07.030] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2006] [Revised: 06/12/2006] [Accepted: 07/10/2006] [Indexed: 11/20/2022]
Abstract
OBJECTIVES We sought to evaluate the effect of the aldosterone synthase promoter polymorphism on heart failure outcomes for subjects in the African American Heart Failure Trial (A-HeFT). BACKGROUND Genetic heterogeneity modulates clinical outcomes in subjects with heart failure (HF); however, little data exist in African American populations. A common polymorphism exists in the promoter region of the aldosterone synthase gene (CYP11B2) at position -344 (T/C). The -344C allele, associated with higher aldosterone synthase activity, has been linked to hypertension; however, its impact on outcomes in HF is unknown. METHODS A total of 354 subjects from A-HeFT participated in the GRAHF (Genetic Risk Assessment of Heart Failure in African Americans) substudy and were genotyped for the aldosterone synthase polymorphism. Patients were followed prospectively, and event-free survival (freedom from death and HF hospitalization) compared by CYP11B2 genotype. RESULTS Of the cohort, 218 patients were TT, 114 CT, and 22 patients were CC. Baseline etiology, blood pressure, and functional class were not significantly different among the 3 cohorts. The C allele was associated with significantly poorer HF hospitalization-free survival with the best survival among TT subjects, intermediate for heterozygotes, and the poorest for CC homozygotes (p = 0.018), and a higher rate of death (% death TT/TC/CC = 1.8/3.5/18.2, p = 0.001). The TT genotype, more prevalent in blacks, was associated with greater impact of fixed combination of isosorbide dinitrate and hydralazine on the primary composite end point (p = 0.01). CONCLUSIONS The aldosterone synthase promoter -344C allele linked to higher aldosterone levels is associated with poorer event-free survival in blacks with HF. The role of aldosterone receptor antagonists in diminishing this apparent genetic risk remains to be explored.
Collapse
Affiliation(s)
- Dennis M McNamara
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Heart failure appears to run in the family. Heart Advis 2006; 9:2. [PMID: 17149804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
|
20
|
Batlle M, Roig E, Perez-Villa F, Lario S, Cejudo-Martin P, García-Pras E, Ortiz J, Roqué M, Orús J, Rigol M, Heras M, Ramírez J, Jimenez W. Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure. J Heart Lung Transplant 2006; 25:1117-25. [PMID: 16962475 DOI: 10.1016/j.healun.2006.04.012] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2006] [Revised: 04/20/2006] [Accepted: 04/24/2006] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND The activation of the renin-angiotensin system (RAS) contributes to the progression of left ventricular dysfunction. A novel human homologue of the angiotensin-converting enzyme (ACE), named ACE2, has been described but its role in human heart failure (HF) has not been elucidated. Besides, there is controversy as to whether the major angiotensin II-forming-activity in heart is ACE or chymase released from mast cells. Furthermore, long-term blockade of nitric oxide (NO) synthesis has been shown to increase ACE activity. To assess the locally activated vasoactive mediators that may contribute to the ventricular deterioration process, we sought to simultaneously analyze their expression in failing hearts. METHODS We analyzed left ventricular biopsies from 30 patients with heart failure undergoing heart transplantation and 12 organ donors. The mRNA levels of ACE, ACE2, chymase and endothelial nitric oxide synthase (eNOS), were quantified by real-time polymerase chain reaction and mast cell density was assessed by immunohistochemistry. The mRNA levels of the atrial natriuretic peptide (ANP) and the brain natriuretic peptide (BNP) were also quantified as controls. RESULTS There was higher ACE and chymase mRNA expression and mast cell density in failing than in control myocardium and no changes in ACE2 expression were detected. eNOS mRNA levels were lower in failing hearts. Both ANP and BNP expression were higher in pathological than in control samples. CONCLUSIONS These data document a decompensation of vasoactive systems that may contribute to the progressive impairment of the myocardial function in HF. On the other hand, ACE2 mRNA expression is not altered in human end-stage HF.
Collapse
MESH Headings
- Adult
- Aged
- Angiotensin-Converting Enzyme 2
- Atrial Natriuretic Factor/genetics
- Atrial Natriuretic Factor/metabolism
- Biopsy
- Cardiac Output, Low/genetics
- Cardiac Output, Low/metabolism
- Cardiac Output, Low/pathology
- Cell Count
- Chymases
- Disease Progression
- Female
- Gene Expression Regulation
- Gene Expression Regulation, Enzymologic
- Humans
- Male
- Mast Cells/metabolism
- Mast Cells/pathology
- Middle Aged
- Natriuretic Peptide, Brain/genetics
- Natriuretic Peptide, Brain/metabolism
- Nitric Oxide Synthase Type III/genetics
- Nitric Oxide Synthase Type III/metabolism
- Peptidyl-Dipeptidase A/genetics
- Peptidyl-Dipeptidase A/metabolism
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Renin-Angiotensin System/genetics
- Renin-Angiotensin System/physiology
- Serine Endopeptidases/genetics
- Serine Endopeptidases/metabolism
- Ventricular Dysfunction, Left/genetics
- Ventricular Dysfunction, Left/metabolism
- Ventricular Dysfunction, Left/pathology
Collapse
Affiliation(s)
- Montserrat Batlle
- Experimental Cardiology Laboratory, Hospital Clínic de Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Hambleton M, Hahn H, Pleger ST, Kuhn MC, Klevitsky R, Carr AN, Kimball TF, Hewett TE, Dorn GW, Koch WJ, Molkentin JD. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 2006; 114:574-82. [PMID: 16880328 PMCID: PMC2707825 DOI: 10.1161/circulationaha.105.592550] [Citation(s) in RCA: 116] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The conventional protein kinase C (PKC) isoform alpha functions as a proximal regulator of Ca2+ handling in cardiac myocytes. Deletion of PKCalpha in the mouse results in augmented sarcoplasmic reticulum Ca2+ loading, enhanced Ca2+ transients, and augmented contractility, whereas overexpression of PKCalpha in the heart blunts contractility. Mechanistically, PKCalpha directly regulates Ca2+ handling by altering the phosphorylation status of inhibitor-1, which in turn suppresses protein phosphatase-1 activity, thus modulating phospholamban activity and secondarily, the sarcoplasmic reticulum Ca2+ ATPase. METHODS AND RESULTS In the present study, we show that short-term inhibition of the conventional PKC isoforms with Ro-32-0432 or Ro-31-8220 significantly augmented cardiac contractility in vivo or in an isolated work-performing heart preparation in wild-type mice but not in PKCalpha-deficient mice. Ro-32-0432 also increased cardiac contractility in 2 different models of heart failure in vivo. Short-term or long-term treatment with Ro-31-8220 in a mouse model of heart failure due to deletion of the muscle lim protein gene significantly augmented cardiac contractility and restored pump function. Moreover, adenovirus-mediated gene therapy with a dominant-negative PKCalpha cDNA rescued heart failure in a rat model of postinfarction cardiomyopathy. PKCalpha was also determined to be the dominant conventional PKC isoform expressed in the adult human heart, providing potential relevance of these findings to human pathophysiology. CONCLUSIONS Pharmacological inhibition of PKCalpha, or the conventional isoforms in general, may serve as a novel therapeutic strategy for enhancing cardiac contractility in certain stages of heart failure.
Collapse
Affiliation(s)
- Michael Hambleton
- Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Toll-like receptors (TLRs) form a family of pattern recognition receptors that have emerged as key mediators of innate immunity. These receptors sense invading microbes and initiate the immune response. TLR-mediated inflammation is an important pathogenic link between innate immunity and a diverse panel of clinical disorders. Among the processes in which TLRs play a role are cardiovascular disorders such as cardiac ischaemia, coronary artery disease, ventricular remodelling, cancer angiogenesis or transplant rejection. From these, many important opportunities for disease modification through TLR signalling manipulation can be imagined. Their role as potential targets for therapeutic intervention is just beginning to be appreciated and this article reviews the current status of these treatment strategies for cardiovascular disease.
Collapse
Affiliation(s)
- Gábor Földes
- Semmelweis University, 1st Department of Medicine, Budapest, Hungary.
| | | | | |
Collapse
|
23
|
Razeghi P, Buksinska-Lisik M, Palanichamy N, Stepkowski S, Frazier OH, Taegtmeyer H. Transcriptional regulators of ribosomal biogenesis are increased in the unloaded heart. FASEB J 2006; 20:1090-6. [PMID: 16770008 DOI: 10.1096/fj.06-5718com] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Mechanical unloading of the rat heart increases both protein synthesis and protein degradation. The transcriptional mechanism underlying increased protein synthesis during atrophic remodeling is not known. The aim of this study was to identify transcriptional regulators and the gene expression profile regulating protein synthesis in the unloaded rat heart and in the unloaded failing human heart. We measured DNA binding activity, transcript levels, and protein expression of transcriptional regulators of protein synthesis in a model of atrophic remodeling induced by heterotopic transplantation of the rat heart (duration 1 and 7 days). Using microarray analysis and quantitative RT-polymerase chain reaction, we found an increase in c-myc-regulated gene expression including an induction of ribosomal subunit messenger RNA's (RPS 10, RPL 21) and rRNA (18S). Consistent with the gene expression profile, DNA binding activity of c-myc and the nuclear protein concentration of its coactivator, upstream binding factor (UBF), increased in the atrophied heart whereas protein levels of the c-myc inhibitor MAD1 decreased. We found the same increase of ribosomal subunit messenger RNA and rRNA in 21 paired samples of failing human hearts obtained before and after left ventricular assist device treatment (mean duration: 157+/-31 days). In summary, mechanical unloading increases c-myc activity and c-myc-regulated gene expression in the rat heart. Changes in transcript levels of genes regulating ribosomal biogenesis in the unloaded rat heart resemble those found in the unloaded failing human heart. We concluded c-myc and c-myc-regulated gene expression are transcriptional regulators of protein synthesis during atrophic remodeling of the heart.
Collapse
Affiliation(s)
- Peter Razeghi
- Division of Cardiology, University of Texas Houston-Medical School, 6431 Fannin, MSB 1.222, Houston, Texas 77030, USA
| | | | | | | | | | | |
Collapse
|
24
|
Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A 2006; 103:10086-91. [PMID: 16775082 PMCID: PMC1502510 DOI: 10.1073/pnas.0603615103] [Citation(s) in RCA: 301] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Heart failure is accompanied by important defects in metabolism. The transcriptional coactivator peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) is a powerful regulator of mitochondrial biology and metabolism. PGC-1alpha and numerous genes regulated by PGC-1alpha are repressed in models of cardiac stress, such as that generated by transverse aortic constriction (TAC). This finding has suggested that PGC-1alpha repression may contribute to the maladaptive response of the heart to chronic hemodynamic loads. We show here that TAC in mice genetically engineered to lack PGC-1alpha leads to accelerated cardiac dysfunction, which is accompanied by signs of significant clinical heart failure. Treating cardiac cells in tissue culture with the catecholamine epinephrine leads to repression of PGC-1alpha and many of its target genes, recapitulating the findings in vivo in response to TAC. Importantly, introduction of ectopic PGC-1alpha can reverse the repression of most of these genes by epinephrine. Together, these data indicate that endogenous PGC-1alpha serves a cardioprotective function and suggest that repression of PGC-1alpha significantly contributes to the development of heart failure. Moreover, the data suggest that elevating PGC-1alpha activity may have therapeutic potential in the treatment of heart failure.
Collapse
Affiliation(s)
- Zoltan Arany
- *Dana–Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, MA 02115; and
| | - Mikhail Novikov
- Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
| | - Sherry Chin
- *Dana–Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, MA 02115; and
| | - Yanhong Ma
- *Dana–Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, MA 02115; and
| | - Anthony Rosenzweig
- Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
| | - Bruce M. Spiegelman
- *Dana–Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, MA 02115; and
| |
Collapse
|
25
|
Leineweber K, Tenderich G, Wolf C, Wagner S, Zittermann A, Elter-Schulz M, Moog R, Müller N, Jakob HG, Körfer R, Philipp T, Heusch G, Brodde OE. Is there a role of the Thr164Ile-β2-adrenoceptor polymorphism for the outcome of chronic heart failure? Basic Res Cardiol 2006; 101:479-84. [PMID: 16783489 DOI: 10.1007/s00395-006-0601-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/27/2006] [Revised: 05/09/2006] [Accepted: 05/10/2006] [Indexed: 11/25/2022]
Abstract
OBJECTIVE The Thr164Ile-beta(2)-adrenoceptor (AR) polymorphism exhibits lower affinities for catecholamines and reduced basal and agonist-stimulated adenylyl cyclase activity in vitro. It has been suggested that patients with chronic heart failure (CHF) due to ischemic or dilated cardiomyopathy carrying the Thr164Ile-beta(2)AR polymorphism exhibit much more rapid progression to death or heart transplantation (HTX) than CHF-patients carrying the homozygous Thr164-beta(2)AR. This study aimed to further evaluate the role of the Thr164Ile-beta(2)AR in CHF. For this we hypothesized that the Thr164Ile-beta(2)AR variant should be more abundant in HTX-patients than in patients with stable CHF or healthy controls. METHODS AND RESULTS We genotyped 309 HTX-patients, 520 stable CHF-patients and 328 healthy controls for the three beta(2)AR variants Arg16Gly, Gln27Glu and Thr164Ile. The prevalence of the Thr164Ile-beta(2)AR variant was not considerably different in HTX-patients (2.3%) from that in CHF-patients (1.9%) or healthy controls (2.1%). Similarly, the frequency of the minor Ile164-allele was f(-)=0.0106 in HTX-patients, f(-)=0.0096 in CHF-patients and f(-)=0.0113 in healthy controls. CONCLUSIONS The prevalence of the hypofunctional Thr164Ile-beta(2)AR variant and the frequency of the Ile164-allele were almost identical in CHF-patients, who had undergone HTX, with those in patients with stable CHF or in healthy controls. Thus, the role of the Thr164Ile-beta(2)AR in CHF remains questionable.
Collapse
Affiliation(s)
- Kirsten Leineweber
- Department of Pathophysiology, University of Essen School of Medicine, Hufelandstr. 55, 45147 Essen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Logeart D, Vinet L, Ragot T, Heimburger M, Louedec L, Michel JB, Escoubet B, Mercadier JJ. Percutaneous intracoronary delivery of SERCA gene increases myocardial function: a tissue Doppler imaging echocardiographic study. Am J Physiol Heart Circ Physiol 2006; 291:H1773-9. [PMID: 16766633 DOI: 10.1152/ajpheart.00411.2006] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The aim of this study was to examine the efficiency of adenovirus-mediated overexpression of sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA1a) gene in a realistic model based on percutaneous intracoronary delivery and on noninvasive functional monitoring. Catheter-based selective coronary delivery of saline or adenoviruses (Ad.CMV.SERCA1a or Ad.CMV.lacZ, 10(10) plaque-forming units) was performed in the circumflex artery of rabbits. Effects were assessed and compared by using serial Doppler echocardiography, hemodynamics, and measurements of SERCA protein and Ca(2+) uptake activity. On day 3, a 21% increase in SERCA proteins and a 37% increase in the maximal rate of Ca(2+) uptake were observed in the transfected left ventricular (LV) walls of Ad.CMV.SERCA1a rabbits. Baseline hemodynamics and conventional echographic measurements of global LV function were poorly affected. In contrast, tissue Doppler imaging (TDI) was able to assess a strong increase in the baseline function of transfected LV walls, as assessed with maximal wall velocities (+32% and +43%, respectively) and strain rates (+18% and +30%, respectively). TDI parameters were closely related to the maximal rate of Ca(2+) uptake (r(2) = 0.68 for the systolic strain rate). Serial TDI analysis during follow-up showed that the effects lasted for 7 days and were no longer detectable 15 days after adenoviruses injection. In conclusion, LV function can be increased by adenovirus-mediated overexpression of SERCA in a clinically relevant model, and TDI provides an accurate and noninvasive tool for monitoring effects on global as well as regional myocardial function.
Collapse
Affiliation(s)
- Damien Logeart
- Service de Cardiologie, Hôpital Lariboisière, 2 rue Ambroise Paré, 75010 Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
|
29
|
Cameron VA, Mocatta TJ, Pilbrow AP, Frampton CM, Troughton RW, Richards AM, Winterbourn CC. Angiotensin Type-1 Receptor A1166C Gene Polymorphism Correlates With Oxidative Stress Levels in Human Heart Failure. Hypertension 2006; 47:1155-61. [PMID: 16651460 DOI: 10.1161/01.hyp.0000222893.85662.cd] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Oxidative stress plays a critical role in the pathogenesis of cardiovascular disease and diabetes. Studies in vascular cells and experimental animals have demonstrated that the angiotensin type-1 receptor (AT1R) contributes to formation of reactive oxygen species by activating nicotinamide-adenine dinucleotide phosphate oxidases, but the relevance of this pathway to human heart disease has not been established. Here we demonstrate that a polymorphism in the
AT1R
gene (A1166C), linked to increased receptor activity, is associated with elevated levels of oxidative stress markers in heart failure patients but not in healthy controls. Plasma protein carbonyls (PCs), a marker of oxidative protein modification, were 10-fold higher in heart-failure patients compared with controls [geometric means and 95% CIs for patients, 75 (57 to 100) pmol/mg; controls, 5 (4 to 7) pmol/mg;
P
<0.001]. Moreover, levels of PCs were 50-fold higher in patients homozygous for the polymorphism (CC) than in controls and significantly higher than the AA and AC genotype patient groups [CC: 273 (135–550); AC: 59 (35–98); AA: 65 (40–106) pmol/mg;
P
<0.001]. Levels of myeloperoxidase were also modestly increased in heart-failure patients [51 (46–57) ng/mL] compared with controls [37 (32–44) ng/mL;
P
<0.001], but were especially elevated in patients with a CC genotype [CC: 72 (58–89); AC: 52 (44–61); AA: 39 (34–46) ng/mL;
P
<0.001]. The
AT1R
genotype was demonstrated to be an independent predictor of both PCs and myeloperoxidase levels in heart-failure patients. These findings suggest that oxidative stress in human heart failure is regulated via angiotensin signaling and may involve the nicotinamide dinucleotide oxidase pathway.
Collapse
Affiliation(s)
- Vicky A Cameron
- Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand.
| | | | | | | | | | | | | |
Collapse
|
30
|
Kovlen DV, Ponomarenko GN, Tishakov AI, Glotov OS, Moskalenko MV, Demin GS, Bratova NI, Ivashchenko TE, Obrezan AG. [The role of gene nets in realization of therapeutic effects of climate therapy in patients with chronic cardiac failure]. Vopr Kurortol Fizioter Lech Fiz Kult 2006:5-9. [PMID: 16862883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
|
31
|
Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, Tatara Y, Shiota A, Sugano S, Takeda S, Rakugi H, Ogihara T. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006; 47:718-26. [PMID: 16505206 DOI: 10.1161/01.hyp.0000205833.89478.5b] [Citation(s) in RCA: 264] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase that cleaves angiotensin II to angiotensin 1-7. Recently, it was reported that mice lacking ACE2 (ACE2(-/y) mice) exhibited reduced cardiac contractility. Because mechanical pressure overload activates the cardiac renin-angiotensin system, we used ACE2(-/y) mice to analyze the role of ACE2 in the response to pressure overload. Twelve-week-old ACE2(-/y) mice and wild-type (WT) mice received transverse aortic constriction (TAC) or sham operation. Sham-operated ACE2(-/y) mice exhibited normal cardiac function and had morphologically normal hearts. In response to TAC, ACE2(-/y) mice developed cardiac hypertrophy and dilatation. Furthermore, their hearts displayed decreased cardiac contractility and increased fetal cardiac gene induction, compared with WT mice. In response to chronic pressure overload, ACE2(-/y) mice developed pulmonary congestion and increased incidence of cardiac death compared with WT mice. On a biochemical level, cardiac angiotensin II concentration and activity of mitogen-activated protein (MAP) kinases were markedly increased in ACE2(-/y) mice in response to TAC. Administration of candesartan, an AT1 subtype angiotensin receptor blocker, attenuated the hypertrophic response and suppressed the activation of MAP kinases in ACE2(-/y) mice. Activation of MAP kinases in response to angiotensin II was greater in cardiomyocytes isolated from ACE2(-/y) mice than in those isolated from WT mice. ACE2 plays an important role in dampening the hypertrophic response to pressure overload mediated by angiotensin II. Disruption of this regulatory function may accelerate cardiac hypertrophy and shorten the transition period from compensated hypertrophy to cardiac failure.
Collapse
Affiliation(s)
- Koichi Yamamoto
- Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Suita, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Emmrich P, Ogunlade V, Gradistanac T, Daneschnejad S, Koch MC, Schober R. [Facioscapulohumeral muscle dystrophy and heart disease]. ACTA ACUST UNITED AC 2005; 94:348-54. [PMID: 15868364 DOI: 10.1007/s00392-005-0223-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2004] [Accepted: 12/28/2004] [Indexed: 10/25/2022]
Abstract
Cardiac involvement is well known in a number of skeletomuscular diseases but not in facio-scapulohumeral muscular dystrophy (FSHD). We report on a 71 year old woman with progressive cardiac insufficiency in FSHD, which was also confirmed by molecular analysis in one of the two daughters affected by the disease. Autopsy of the deceased patient showed the typical changes in skeletal muscles including focal inflammatory infiltrates in the diaphragm and, in addition, cardiac muscular involvement. The histological changes resembled those seen in primary cardiomyopathy despite the normal muscle mass volume. Both clinically and morphologically, the cardiac disease was the cause of death in this patient with FSHD.
Collapse
MESH Headings
- Aged
- Cardiac Output, Low/diagnosis
- Cardiac Output, Low/genetics
- Cardiac Output, Low/pathology
- Cardiomyopathies/diagnosis
- Cardiomyopathies/genetics
- Cardiomyopathies/pathology
- Chromosome Aberrations
- Chromosome Deletion
- Chromosomes, Human, Pair 4
- Female
- Genes, Dominant
- Heart Failure/diagnosis
- Heart Failure/genetics
- Heart Failure/pathology
- Humans
- Muscle, Skeletal/pathology
- Muscular Dystrophy, Facioscapulohumeral/diagnosis
- Muscular Dystrophy, Facioscapulohumeral/genetics
- Muscular Dystrophy, Facioscapulohumeral/pathology
- Myocardium/pathology
- Pedigree
- Pulmonary Embolism/diagnosis
- Pulmonary Embolism/genetics
- Pulmonary Embolism/pathology
- Ventricular Dysfunction, Left/diagnosis
- Ventricular Dysfunction, Left/genetics
- Ventricular Dysfunction, Left/pathology
Collapse
Affiliation(s)
- P Emmrich
- Selbst. Abt. für Neuropathologie, Institut für Pathologie des Universitätsklinikums Leipzig (AöR), Liebigstr. 26, 04103 Leipzig, Germany
| | | | | | | | | | | |
Collapse
|
33
|
Affiliation(s)
- Carmen C Sucharov
- Division of Cardiology, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
| |
Collapse
|
34
|
Vanderheyden M, Paulus WJ, Voss M, Knuefermann P, Sivasubramanian N, Mann D, Baumgarten G. Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. Heart 2005; 91:926-31. [PMID: 15958363 PMCID: PMC1768970 DOI: 10.1136/hrt.2004.035733] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVE To investigate cytokine gene expression in patients with aortic valve stenosis (AS) and with idiopathic dilated cardiomyopathy (DCM), and to correlate wall stress with myocardial proinflammatory cytokine gene expression. METHODS Human left ventricular (LV) myocardial biopsies were obtained for subsequent reverse transcription polymerase chain reaction of tumour necrosis factor alpha (TNFalpha), interleukin (IL)-1beta, and IL-6 mRNA. The study population consisted of 24 patients with AS and 10 patients with idiopathic DCM. RESULTS Patients with AS had a larger ejection fraction (56 (5) v 37 (4)%, p < 0.01), smaller LV end diastolic volumes (146 (11) v 267 (21) ml, p < 0.01), and lower end systolic wall stress (44 (7) v 112 (11) kdyn/cm2, p < 0.001). Upregulation of TNFalpha, IL-1beta, and IL-6 gene expression was detected in both groups. However, TNFalpha gene expression was significantly higher in AS than in DCM (p = 0.009). No correlation was found between haemodynamic parameters and TNFalpha gene expression. In patients with AS there was a strong inverse relation between circulating TNFalpha and TNFalpha gene expression (r = -0.685, p = 0.014), between circulating TNFalpha and IL-1beta gene expression (r = -0.664, p = 0.018), and between soluble TNF receptor 2 and TNFalpha gene expression (r = -0.685, p = 0.020). Myocardial gene expression of TNFalpha was significantly higher in patients with well compensated AS than in patients with decompensated AS (p = 0.017). Similarly, patients with decompensated DCM were characterised by significantly lower TNFalpha gene expression than were patients with well compensated DCM (p = 0.011). CONCLUSION TNFalpha gene expression is significantly higher in patients with pressure overload than in normal hearts, in patients with idiopathic DCM, and in patients with compensated versus decompensated heart failure. Secondly, in patients with AS proinflammatory cytokine gene expression did not affect systolic performance. The higher TNFalpha gene expression in patients with compensated heart failure suggests that cytokine gene expression has an adaptive role in the early phase of LV remodelling.
Collapse
MESH Headings
- Aged
- Aortic Valve Stenosis/complications
- Aortic Valve Stenosis/genetics
- Aortic Valve Stenosis/physiopathology
- Cardiac Output, Low/complications
- Cardiac Output, Low/genetics
- Cardiac Output, Low/physiopathology
- Cardiomyopathy, Dilated/complications
- Cardiomyopathy, Dilated/genetics
- Cardiomyopathy, Dilated/physiopathology
- Cytokines/blood
- Cytokines/genetics
- Female
- Gene Expression Regulation/genetics
- Hemodynamics/physiology
- Humans
- Interleukin-1/blood
- Interleukin-1/genetics
- Interleukin-6/blood
- Interleukin-6/genetics
- Male
- Middle Aged
- Myocardium/chemistry
- Receptors, Tumor Necrosis Factor, Type II/blood
- Tumor Necrosis Factor-alpha/analysis
- Tumor Necrosis Factor-alpha/genetics
- Up-Regulation/genetics
- Ventricular Dysfunction, Left/complications
- Ventricular Dysfunction, Left/genetics
- Ventricular Dysfunction, Left/physiopathology
Collapse
Affiliation(s)
- M Vanderheyden
- Cardiovascular Centre, Onze Lieve Vrouw Ziekenhuis, Moorselbaan 164, 9400 Aalst, Belgium.
| | | | | | | | | | | | | |
Collapse
|
35
|
Kang D, Hamasaki N. Alterations of mitochondrial DNA in common diseases and disease states: aging, neurodegeneration, heart failure, diabetes, and cancer. Curr Med Chem 2005; 12:429-41. [PMID: 15720251 DOI: 10.2174/0929867053363081] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
It has long been considered that mitochondrial DNA disease is a rare genetic disorder causing neuromyopathy. However, alterations of mitochondrial DNA recently have been recognized to play an important role in the pathogenesis of so-called common diseases such as heart failure, diabetes, and cancer. Although some of these alterations are inherited, more and more attention is being focused on the accumulation of mitochondrial DNA mutations in somatic cells, particularly terminally differentiated cells such as cardiomyocytes and neurons that occurs with age. Mitochondrial DNA is more vulnerable to alteration than nuclear DNA, mainly for two reasons. First, mitochondria are a major source of intracellular reactive oxygen species (ROS). Therefore mitochondrial DNA is under much stronger oxidative stress than is nuclear DNA. Second, mitochondria have a matrix-side negative membrane potential for oxidative phosphorylation. This membrane potential concentrates lipophilic cations inside mitochondria up to approximately 1,000-fold. Unfortunately, some therapeutic reagents are lipophilic cations, and such exogenously added chemicals are prone to damage mitochondria. AZT, an anti-HIV drug, causes mitochondrial myopathy as a side effect, which is a typical example of how chemotherapeutics adversely affect metabolism of mitochondrial DNA. In this review, we focus on ROS and chemical damage of mitochondrial DNA in common diseases.
Collapse
Affiliation(s)
- Dongchon Kang
- Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
| | | |
Collapse
|
36
|
Abstract
Factors that render patients with cardiovascular disease at high risk for heart failure remain incompletely defined. Recent insights into molecular genetic causes of myocardial diseases have highlighted the importance of single-gene defects in the pathogenesis of heart failure. Through analyses of the mechanisms by which a mutation selectively perturbs one component of cardiac physiology and triggers cell and molecular responses, studies of human gene mutations provide a window into the complex processes of cardiac remodeling and heart failure. Knowledge gleaned from these studies shows promise for defining novel therapeutic targets for genetic and acquired causes of heart failure.
Collapse
Affiliation(s)
- Hiroyuki Morita
- Department of Genetics, Harvard Medical School, Division of Cardiology, Brigham and Women's Hospital, and Howard Hughes Medical Institute, Boston, Massachusetts 02115, USA
| | | | | |
Collapse
|
37
|
Abstract
Structural and functional alterations in the Ca2+ regulatory proteins present in the sarcoplasmic reticulum have recently been shown to be strongly involved in the pathogenesis of heart failure. Chronic activation of the sympathetic nervous system or of the renin-angiotensin system induces abnormalities in both the function and structure of these proteins. We review here the considerable body of evidence that has accumulated to support the notion that such abnormalities contribute to a defectiveness of contractile performance and hence to the progression of heart failure.
Collapse
Affiliation(s)
- Masafumi Yano
- Department of Medical Bioregulation, Division of Cardiovascular Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan
| | | | | |
Collapse
|
38
|
Abstract
In response to acute and chronic stresses, the heart frequently undergoes a remodeling process that is accompanied by myocyte hypertrophy, impaired contractility, and pump failure, often culminating in sudden death. The existence of redundant signaling pathways that trigger heart failure poses challenges for therapeutic intervention. Cardiac remodeling is associated with the activation of a pathological gene program that weakens cardiac performance. Thus, targeting the disease process at the level of gene expression represents a potentially powerful therapeutic approach. In this review, we describe strategies for normalizing gene expression in the failing heart with small molecules that control signal transduction pathways directed at transcription factors and associated chromatin-modifying enzymes.
Collapse
|
39
|
Abstract
Cardiac hypertrophy in response to pressure overload is initially beneficial but eventually leads to heart failure, a major cause of morbidity and mortality in the Western countries. Although abnormalities in left ventricular (LV) diastolic filling are early features associated with pressure overload-induced LV hypertrophy, the molecular mechanisms regulating transition to diastolic heart failure are poorly understood. We analyzed global changes in gene expression in 12-, 16-, and 20-month-old spontaneously hypertensive rats (SHR) and their age-matched controls, Wistar Kyoto rats, using DNA microarrays. In SHR, a progressive LV hypertrophy was associated with increased expression of hypertrophy-associated genes including contractile protein and natriuretic peptide genes. Echocardiography indicated that 16-month-old SHR had features of diastolic dysfunction leading to diastolic failure at age 20 months without significant changes in LV systolic function. Comparison analysis revealed that the extracellular matrix genes strikingly dominated the list of altered genes after transition to the heart failure, whereas there was no major shift in gene expression patterns involved in calcium homeostasis and neurohumoral activation, as well as myofilament contractile and cytoskeletal proteins. The microarray analysis also revealed differential gene expression of several novel factors, such as thrombospondin-4 and matrix Gla protein, as well as unknown expressed sequence tags. Our data show that transition from LV hypertrophy to diastolic hypertensive heart failure is almost exclusively associated with progressive remodeling of the extracellular matrix and provide new insights into the pathogenesis of hypertrophy by suggesting existence of novel regulators of LV remodeling.
Collapse
Affiliation(s)
- Jaana Rysä
- Department of Pharmacology and Toxicology, Biocenter Oulu, University of Oulu, Oulu, Finland
| | | | | | | |
Collapse
|
40
|
Du XJ, Fang L, Gao XM, Kiriazis H, Feng X, Hotchkin E, Finch AM, Chaulet H, Graham RM. Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction. J Mol Cell Cardiol 2005; 37:979-87. [PMID: 15522275 DOI: 10.1016/j.yjmcc.2004.07.010] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2004] [Revised: 07/09/2004] [Accepted: 07/29/2004] [Indexed: 11/22/2022]
Abstract
In response to pressure-overload, cardiac function deteriorates and may even progress to fulminant heart failure and death. Here we questioned if genetic enhancement of left ventricular (LV) contractility protects against pressure-overload. Transgenic (TG) mice with cardiac-restricted overexpression (66-fold) of the alpha(1A)-adrenergic receptor (alpha(1A)-AR) and their non-TG (NTG) littermates, were subjected to transverse aorta constriction (TAC)-induced pressure-overload for 12 weeks. TAC-induced hypertrophy was similar in the NTG and TG mice but the TG mice were less likely to die of heart failure compared to the non-TG animals (P <0.05). The hypercontractile phenotype of the TG mice was maintained over the 12-week period following TAC with LV fractional shortening being significantly greater than in the NTG mice (42+/-2 vs 29+/-1%, P <0.01). In the TG animals, 11-week beta-AR-blockade with atenolol neither induced hypertrophy nor suppressed the hypercontractile phenotype. The hypertrophic response to pressure-overload was not altered by cardiac alpha(1A)-AR overexpression. Moreover, the inotropic phenotype of alpha(1A)-AR overexpression was well maintained under conditions of pressure overload. Although the functional decline in contractility with pressure overload was similar in the TG and NTG animals, given that contractility was higher before TAC in the TG mice, their LV function was better preserved and heart failure deaths were fewer after induction of pressure overload.
Collapse
MESH Headings
- Actins/genetics
- Animals
- Antihypertensive Agents/pharmacology
- Atenolol/pharmacology
- Atrial Natriuretic Factor/genetics
- Blood Pressure/drug effects
- Blood Pressure/genetics
- Blood Pressure/physiology
- Cardiac Myosins/genetics
- Cardiac Output, Low/etiology
- Cardiac Output, Low/genetics
- Cardiac Output, Low/prevention & control
- Constriction
- Electrocardiography
- Gene Expression/genetics
- Genetic Enhancement
- Hypertrophy, Left Ventricular/etiology
- Hypertrophy, Left Ventricular/genetics
- Hypertrophy, Left Ventricular/prevention & control
- Mice
- Mice, Transgenic
- Myocardial Contraction/genetics
- Myocardial Contraction/physiology
- Myosin Light Chains/genetics
- Receptors, Adrenergic, alpha-1/genetics
- Receptors, Adrenergic, alpha-1/physiology
- Ventricular Function
Collapse
Affiliation(s)
- Xiao-Jun Du
- Baker Heart Research Institute, Commercial Road, Victoria 3004, Melbourne, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Kiji T, Dohi Y, Takasawa S, Okamoto H, Nonomura A, Taniguchi S. Activation of regenerating gene Reg in rat and human hearts in response to acute stress. Am J Physiol Heart Circ Physiol 2005; 289:H277-84. [PMID: 15778284 DOI: 10.1152/ajpheart.01206.2004] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Recently, the regenerating gene (Reg) has been documented to play an important role in various regenerating tissues, but it is unknown whether the Reg gene could be activated in the heart. The aim of this study was to reveal the transcriptional activation of Reg in the heart in response to heart stress. We first found REG-1 protein expression in human hearts obtained from autopsied patients who died of myocardial infarction. REG protein was immunohistochemically stained in a fine granular pattern in the cytoplasm of cardiomyocytes. To demonstrate the activation profiles of Reg gene expression in the heart, we quantified the levels of Reg-1 mRNA in rat hearts after coronary artery ligation using real-time RT-PCR. Transient Reg-1 mRNA activation, peaking at 12 h after coronary ligation, was observed mainly in the atria, which was sevenfold higher compared with hearts with pressure overload due to aortic constriction. In contrast, Reg receptor mRNA was expressed intensely in damaged ventricles. Furthermore, Western blot analysis showed the corresponding pattern of Reg protein secretion into the serum after loading, and circulating levels of the protein after myocardial infarction were higher than those after aortic constriction. In conclusion, our results demonstrate for the first time the presence of the Reg/Reg receptor system in damaged hearts. In view of emerging evidence of Reg for tissue regeneration in a variety of tissues/organs, it is proposed that the damaged heart may be a target for Reg action and that Reg may protect against acute heart stress.
Collapse
Affiliation(s)
- Tatsuya Kiji
- Dept. of Thoracic and Cardiovascular Surgery, Nara Medical Univ. School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
| | | | | | | | | | | |
Collapse
|
42
|
|
43
|
Abstract
A growing body of evidence, including studies using genetically engineered mouse models, has shown that Ca2+ cycling and Ca2+-dependent signaling pathways play a pivotal role in cardiac hypertrophy and heart failure. In addition, recent studies identified that mutations of the genes encoding sarcoplasmic reticulum (SR) proteins cause human cardiomyopathies and lethal ventricular arrhythmias. The regulation of Ca2+ homeostasis via the SR proteins may have potential therapeutic value for heart diseases such as cardiomyopathy, heart failure and arrhythmias.
Collapse
Affiliation(s)
- Susumu Minamisawa
- Department of Physiology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
| | | | | |
Collapse
|
44
|
Abstract
Heart failure is a major disease burden worldwide, and its incidence continues to increase as premature deaths from other cardiovascular conditions decline. Although the overall molecular portrait of this multifactorial disease remains incomplete, molecular and genetic studies have implicated, in recent decades, various pathways and genes that participate in the pathophysiology of heart failure. Here, we highlight the current understanding of the molecular and genetic basis of heart failure and show how recently developed genomic tools are providing a new perspective on this complex disease.
Collapse
Affiliation(s)
- Choong-Chin Liew
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 77 Louis Pasteur Avenue, NRB room 0630K, Boston, Massachusetts 02115, USA.
| | | |
Collapse
|
45
|
Mallat Z, Heymes C, Corbaz A, Logeart D, Alouani S, Cohen-Solal A, Seidler T, Hasenfuss G, Chvatchko Y, Shah AM, Tedgui A. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J 2004; 18:1752-4. [PMID: 15371332 DOI: 10.1096/fj.04-2426fje] [Citation(s) in RCA: 116] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Interleukin (IL)-18 is the interferon-gamma-inducing factor and has potent proinflammatory activities. IL-18 has been recently implicated in atherosclerotic plaque instability and myocardial ischemia-reperfusion injury. However, it is unknown whether IL-18 expression is increased in human myocardium or if it has any role in heart failure. We analyzed the expression of IL-18, its receptor IL-18Ralpha, and its endogenous inhibitor, IL-18 binding protein (IL-18BP) in myocardial tissue from patients with end-stage heart failure (ischemic or dilated cardiomyopathy) and controls by use of quantitative real-time reverse transcriptase polymerase chain reaction, Western blot or immunohistochemical techniques. Plasma levels of IL-18 were also determined in 48 patients with heart failure. IL-18 mRNA and protein levels were up-regulated in the myocardium of patients with ischemic cardiomyopathy. Both ischemic and dilated myocardium showed increased IL-18Ralpha levels, suggesting potential biological effects. In addition, mRNA levels of IL-18 BP were down-regulated in the failing myocardium. Finally, plasma IL-18 levels were significantly elevated in patients with heart failure and were higher in those who died at follow-up than in survivors. The results suggest a potential role for the immunoinflammatory IL-18 signaling pathway in the pathophysiology of heart failure and identify novel therapeutic targets for future testing.
Collapse
Affiliation(s)
- Ziad Mallat
- Institut Fédératif de Recherche Paris VII, INSERM U541, Hôpital Lariboisière, 41 Blvd. de la Chapelle, 75475 Paris Cedex 10, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JPM, Porter JG, Evelo CTA, Duisters R, van Leeuwen REW, Janssen BJA, Debets JJM, Smits JFM, Daemen MJAP, Crijns HJGM, Bornstein P, Pinto YM. Thrombospondin-2 Is Essential for Myocardial Matrix Integrity. Circ Res 2004; 95:515-22. [PMID: 15284191 DOI: 10.1161/01.res.0000141019.20332.3e] [Citation(s) in RCA: 145] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cardiac hypertrophy can lead to heart failure (HF), but it is unpredictable which hypertrophied myocardium will progress to HF. We surmised that apart from hypertrophy-related genes, failure-related genes are expressed before the onset of failure, permitting molecular prediction of HF. Hearts from hypertensive homozygous renin-overexpressing (Ren-2) rats that had progressed to early HF were compared by microarray analysis to Ren-2 rats that had remained compensated. To identify which HF-related genes preceded failure, cardiac biopsy specimens were taken during compensated hypertrophy and we then monitored whether the rat progressed to HF or remained compensated. Among 48 genes overexpressed in failing hearts, we focused on thrombospondin-2 (TSP2). TSP2 was selectively overexpressed only in biopsy specimens from rats that later progressed to HF. Moreover, expression of TSP2 was increased in human hypertrophied hearts with decreased (0.19+/-0.01) versus normal ejection fraction (0.11+/-0.03 [arbitrary units]; P<0.05). Angiotensin II induced fatal cardiac rupture in 70% of TSP2 knockout mice, with cardiac failure in the surviving mice; this was not seen in wild-type mice. In TSP2 knockout mice, angiotensin II increased matrix metalloproteinase (MMP)-2 and MMP-9 activity by 120% and 390% compared with wild-type mice (P<0.05). In conclusion, we identify TSP2 as a crucial regulator of the integrity of the cardiac matrix that is necessary for the myocardium to cope with increased loading and that may function by its regulation of MMP activity. This suggests that expression of TSP2 marks an early-stage molecular program that is activated uniquely in hypertrophied hearts that are prone to fail.
Collapse
Affiliation(s)
- Blanche Schroen
- Experimental and Molecular Cardiology/CARIM, University of Maastricht, Maastricht, the Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
del Monte F, Kizana E, Tabchy A, Hajjar RJ. Targeted gene transfer in heart failure: implications for novel gene identification. Curr Opin Mol Ther 2004; 6:381-94. [PMID: 15468597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
Heart failure remains an intractable disease with epidemic proportions in the Western World. While progress in conventional treatment modalities for congestive heart failure is making steady and incremental gains to reduce this disease burden, there remains a need to explore new potentially therapeutic approaches. Gene therapy, for example, was initially envisioned as a treatment strategy for inherited monogenic disorders. It is now apparent that gene therapy has broader potential that also includes acquired polygenic diseases, such as heart failure. Advances in the understanding of the molecular basis of congestive heart failure, together with the evolution of increasingly efficient gene transfer technology, has placed congestive heart failure within reach of gene-based therapy. In addition, gene-based reconstitution of a normal phenotype allows us to closely examine the behavior of a large number of transcripts as the heart fails and is rescued by genetic manipulations.
Collapse
Affiliation(s)
- Federica del Monte
- Harvard Medical School, Massachusetts General Hospital, Cardiology Division, Cardiology Laboratory of Integrative Physiology and Imaging, 55 Fruit Street, Boston, MA 02115, USA
| | | | | | | |
Collapse
|
48
|
Michele DE, Szatkowski ML, Albayya FP, Metzger JM. Parvalbumin gene delivery improves diastolic function in the aged myocardium in vivo. Mol Ther 2004; 10:399-403. [PMID: 15294186 DOI: 10.1016/j.ymthe.2004.05.011] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2003] [Accepted: 05/07/2004] [Indexed: 10/26/2022] Open
Abstract
Abnormal relaxation of the heart, termed diastolic dysfunction, is a significant and growing problem that is a major cause of heart failure in the aged population. The potential of gene transfer of parvalbumin (Parv), a cytoplasmic calcium-binding protein, to improve diastolic function in the aged myocardium in vivo was evaluated. Despite evidence for an early developmental influence on the efficiency of Ad5 striated muscle transduction, results show that Ad5 gene transfer efficiency to adult cardiac myocytes in vitro is identical in young and old rats, suggesting that the basic processes of adenovirus binding and internalization are unaffected by aging. In contrast, Ad5-mediated Parv gene transfer to the myocardium in vivo is reduced in old rats compared to young rats. Nonetheless, Parv gene transfer and expression in vivo were sufficient to improve tau, a load-independent indicator of diastolic function, assessed using catheter-based micromanometry in the aged myocardium. These results suggest that expression of the calcium buffer Parv may represent an effective approach to functional correction of the failing heart in the aging.
Collapse
Affiliation(s)
- Daniel E Michele
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA
| | | | | | | |
Collapse
|
49
|
Del Monte F, Dalal R, Tabchy A, Couget J, Bloch KD, Peterson R, Hajjar RJ. Transcriptional changes following restoration of SERCA2a levels in failing rat hearts. FASEB J 2004; 18:1474-6. [PMID: 15247151 DOI: 10.1096/fj.04-1714fje] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Heart failure is characterized at the cellular level by impaired contractility and abnormal Ca2+ homeostasis. We have previously shown that restoration of a key enzyme that controls intracellular Ca(2+) handling, the sarcoplasmic reticulum Ca2+ ATPase (SERCA2a), induces functional improvement in heart failure. We used high-density oligonucleotide arrays to explore the effects of gene transfer of SERCA2a on genetic reprogramming in a model of heart failure. A total of 1,300 transcripts were identified to be unmodified by the effect of virus alone. Of those, 251 transcripts were found to be up- or down-regulated upon failure. A total of 51 transcripts which were either up--(27) or down--(24) regulated in heart failure were normalized to the nonfailing levels by the restoration of SERCA2a by gene transfer. The microarray analysis identified new genes following SERCA2a restoration in heart failure, which will give us insights into their role in the normalization of multiple pathways within the failing cell.
Collapse
Affiliation(s)
- Federica Del Monte
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
| | | | | | | | | | | | | |
Collapse
|
50
|
Vasků A, Goldbergová M, Hollá LI, Spinarová L, Spinar J, Vítovec J, Vácha J. Two MMP-2 promoter polymorphisms (-790T/G and -735C/T) in chronic heart failure. Clin Chem Lab Med 2004; 41:1299-303. [PMID: 14580155 DOI: 10.1515/cclm.2003.197] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Remodelling of extracellular matrix by activated matrix metalloproteinases is considered to contribute to progression of ventricle remodelling during chronic heart failure. The aim of this study was to associate two promoter polymorphisms, -790T/G and -735C/T, in the gene for matrix metalloproteinase (MMP)-2 (gelatinase A) with chronic heart failure (CHF). For this purpose, 164 patients (124 men, 40 women, median age 56 years, range 21-91 years) with CHF (functional class NYHA II-IV, ejection fraction median 25%, cardiothoracic index more than 50%) were compared with 196 control subjects without clinical signs of cardiovascular disease (131 men and 65 women, median age 56 years, range 27-84 years) in -790T/G and -735C/T MMP-2 genotype distributions and allelic frequencies. The genotypes were determined by polymerase chain reaction (PCR) with restriction analyses. A significant increase of the T allele of the -790T/G MMP-2 polymorphism (p = 0.04), as well as of the C allele of the -735C/T MMP-2 gene polymorphism, in patients with CHF was proven (p = 0.04). The heterozygote CT of the -735C/T MMP-2 polymorphism exhibits a 7 times higher odds ratio (OR) for the CHF patients with lower levels of total cholesterol (less than 5 mmol/l), especially for non-hypertensive CHF men (OR = 7.28, 95% confidence interval 1.51-35.03, p = 0.006). Determination of MMP polymorphisms in the regulatory area of the gene could help us to comprehend individual susceptibility of patients with CHF to MMP inhibitors based on known risks of MMP genotypes.
Collapse
Affiliation(s)
- Anna Vasků
- Institute of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
| | | | | | | | | | | | | |
Collapse
|